| 1.08 0.06 (5.88%) | 02-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.45 |
1-year : | 3.25 |
| Resists | First : | 2.1 |
Second : | 2.78 |
| Pivot price | 1.2 |
|||
| Supports | First : | 0.99 | Second : | 0.82 |
| MAs | MA(5) : | 1.1 |
MA(20) : | 1.26 |
| MA(100) : | 0.98  |
MA(250) : | 1.03 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 7.9 |
D(3) : | 5.1 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 3.79 | Low : | 0.57 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HOTH ] has closed above bottom band by 14.3%. Bollinger Bands are 28% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.09 - 1.1 | 1.1 - 1.11 |
| Low: | 0.98 - 0.99 | 0.99 - 1 |
| Close: | 1.07 - 1.08 | 1.08 - 1.09 |
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Mon, 10 Feb 2025
Hoth Therapeutics to Present at the LD Micro Main Event (XII) - ACCESS Newswire
Mon, 10 Feb 2025
Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic - Contract Pharma
Mon, 10 Feb 2025
HOTH's Cancer Breakthrough: Strategic Alliance Accelerates Novel HT-KIT Therapeutic Research - StockTitan
Mon, 10 Feb 2025
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic - PR Newswire
Fri, 07 Feb 2025
Hoth Therapeutics expands at-the-market offering by $5 million - Investing.com
Fri, 24 Jan 2025
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 5.5 (%) |
| Shares Short | 659 (K) |
| Shares Short P.Month | 291 (K) |
| EPS | -1.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.2 % |
| Return on Equity (ttm) | -83.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.86 |
| PEG Ratio | 0 |
| Price to Book value | 0.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|